West Asia conflict hits PE-VC funding in Q1 of CY2026
02 Apr 2026
Catalyst Trusteeship Limited has made a regulatory disclosure regarding the pledge of additional equity shares of OneSource Specialty Pharma Limited under SEBI's substantial acquisition regulations. The disclosure pertains to 28,36,811 additional equity shares pledged by Tenshi Pharmaceuticals Private Limited in multiple tranches.
Share Pledge Details
The additional pledge increases Catalyst Trusteeship's total encumbered shareholding in OneSource Specialty Pharma to 92,36,811 equity shares, representing 8.06% of the company's issued and paid-up share capital. Prior to this transaction, the debenture trustee held pledge over 64,00,000 shares (5.59%).
Parameter: Details Additional Shares Pledged: 28,36,811 Percentage of Share Capital: 2.47% Total Pledged Shares: 92,36,811 Total Percentage: 8.06% Pledgor: Tenshi Pharmaceuticals Private Limited
Transaction Background
The pledge arrangement stems from debentures issued by Karuna Ventures Private Limited, a group company of Tenshi Pharmaceuticals. The debentures are zero coupon, secured, unrated, unlisted, redeemable non-convertible instruments aggregating up to INR 1000,00,00,000. The pledge was created under an amended and restated share pledge agreement dated March 09, 2026.
Tenshi Pharmaceuticals currently holds 2,10,89,714 equity shares in OneSource Specialty Pharma, constituting 18.4% of the issued and paid-up share capital. The company's total equity share capital stands at 11,45,85,136 paid-up equity shares of INR 1 each.
Pledge Creation Timeline
The additional shares were pledged across multiple dates in 2026:
Date: Shares Pledged Percentage January 29, 2026: 7,50,000 0.65% February 05, 2026: 7,15,000 0.62% March 27, 2026: 11,64,607 1.02% March 27, 2026: 2,07,204 0.18%
Regulatory Compliance
Catalyst Trusteeship Limited, acting as debenture trustee, made this disclosure under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. The disclosure was signed by Deesha Srikanth, Senior Vice President, and dated April 01, 2026. OneSource Specialty Pharma's shares are listed on both BSE Limited and National Stock Exchange of India Limited.
OneSource Specialty Pharma Limited's Board of Directors has made strategic decisions regarding the progression of its composite scheme of arrangement and amalgamation. The board has determined to conduct additional review before approaching the National Company Law Tribunal (NCLT) for the proposed acquisition of Steriscience facilities in Poland and Baroda.
Composite Scheme Framework
The comprehensive merger involves multiple entities in a complex arrangement structure. The scheme encompasses the acquisition of Steriscience facilities and involves several key stakeholders working together in a merger by absorption framework.
Parameter: Details Scheme Type: Composite Scheme of Arrangement and Amalgamation Target Facilities: Steriscience Poland and Baroda Operations Regulatory Framework: Sections 230-232, 234, 52, 66 of Indian Companies Act 2013 Singapore Compliance: Sections 210, 212 of Singapore Companies Act 1967 Current Status: Additional review phase before NCLT filing
Board Decision and Strategic Timeline
The board has decided to undertake a more comprehensive review process before proceeding with the NCLT application. This strategic decision reflects the company's commitment to thorough due diligence in the complex multi-jurisdictional acquisition process.
The company will complete this additional review within the six-month approval period that has been established. This timeline ensures adequate evaluation while maintaining progress momentum in the acquisition proceedings.
Regulatory Compliance Status
OneSource Specialty Pharma has maintained proper regulatory compliance throughout the process. The company had previously received in-principle approval from stock exchanges for the proposed scheme, establishing a solid foundation for the merger proceedings.
Compliance Aspect: Status Stock Exchange Approval: In-principle approval received Review Timeline: Six-month approval period NCLT Filing: Pending additional review completion Stakeholder Communication: Ongoing updates committed
Future Acquisition Impact
The proposed acquisition of Steriscience's Poland and Baroda facilities represents a significant expansion opportunity for OneSource Specialty Pharma. Once completed, the integration will potentially enhance the company's manufacturing capabilities and strengthen its geographical presence in key markets.
The company has assured continued transparent communication with regulatory authorities and stakeholders regarding further developments in this acquisition process.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
